SNTS Share Price

Open 31.99 Change Price %
High 32.04 1 Day -0.01 -0.03
Low 31.96 1 Week 0.00 0.00
Close 31.96 1 Month 0.00 0.00
Volume 5682564 1 Year 0.00 0.00
52 Week High 0.40
52 Week Low 0.25
SNTS Important Levels
Resistance 2 32.03
Resistance 1 32.00
Pivot 31.99
Support 1 31.92
Support 2 31.89
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Santarus, Inc. (NASDAQ: SNTS)

SNTS Technical Analysis 5
As on 31st Dec 2013 SNTS Share Price closed @ 31.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 22.17 & Strong Buy for SHORT-TERM with Stoploss of 29.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
SNTS Target for June
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SNTS Other Details
Segment EQ
Market Capital 577287168.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
SNTS Address
SNTS
N/A
SNTS Latest News
Interactive Technical Analysis Chart Santarus, Inc. ( SNTS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Santarus, Inc.
SNTS Business Profile
Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company�s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company�s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.